Guvenius Daiva Meironyté, Hassanzadeh Pari, Bergman Ake, Norén Koidu
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Environ Toxicol Chem. 2002 Nov;21(11):2264-9.
A method for analysis of hydroxylated metabolites of polychlorinated biphenyls (OH-PCBs) was developed and adopted to the previously described method for determination of PCBs and methylsulfonyl-PCBs (MeSO2-PCBs) in human liver and adipose tissue. The concentrations of OH-PCBs (14 congeners), MeSO2-PCBs (24 congeners), and PCBs (17 congeners) in five paired samples of human liver and adipose tissue are reported. The sum of OH-PCB congeners was higher in liver (7-175 ng/g lipids) than in adipose tissue (0.3-9 ng/g lipids). In both liver and adipose tissue, 2,2',3,4,4',5'-hexachloro-3'-biphenylol (3'-OH-CB138) and 2,2',3,3',4,5'-hexachloro-4'-biphenylol (4'-OH-CB130) were the predominant hydroxylated PCB metabolites. The sum of OH-PCB congeners were of the same order of magnitude as those of methylsulfonyl metabolites of PCB in the same samples, 12 to 358 ng/g lipids and 2 to 9 ng/g lipids in liver and adipose tissue, respectively. The levels of PCBs were similar in liver and adipose tissue, 459 to 2,085 ng/g lipids and 561 to 2,343 ng/g lipids, respectively. The sum of OH-PCBs and the sum of MeSO2-PCBs correlated to the sum of PCBs. The determined PCB metabolites constituted 3 to 26% of total PCB concentration in the liver and 0.3 to 0.8% of total PCBs in the adipose tissue samples.
开发了一种多氯联苯羟基化代谢物（OH-PCBs）的分析方法，并将其应用于先前描述的人肝脏和脂肪组织中多氯联苯（PCBs）和甲基磺酰基多氯联苯（MeSO2-PCBs）的测定方法。报告了五对人肝脏和脂肪组织样本中OH-PCBs（14种同系物）、MeSO2-PCBs（24种同系物）和PCBs（17种同系物）的浓度。OH-PCBs同系物的总和在肝脏中（7-175 ng/g脂质）高于脂肪组织（0.3-9 ng/g脂质）。在肝脏和脂肪组织中，2,2',3,4,4',5'-六氯-3'-联苯醇（3'-OH-CB138）和2,2',3,3',4,5'-六氯-4'-联苯醇（4'-OH-CB130）是主要的羟基化多氯联苯代谢物。OH-PCBs同系物的总和与同一样本中多氯联苯甲基磺酰基代谢物的总和处于同一数量级，在肝脏和脂肪组织中分别为12至358 ng/g脂质和2至9 ng/g脂质。PCBs的水平在肝脏和脂肪组织中相似，分别为459至2,085 ng/g脂质和561至2,343 ng/g脂质。OH-PCBs总和与MeSO2-PCBs总和与PCBs总和相关。所测定的多氯联苯代谢物占肝脏中多氯联苯总浓度的3%至26%，占脂肪组织样本中多氯联苯总量的0.3%至0.8%。
